191 related articles for article (PubMed ID: 12865414)
1. Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis.
Jambou F; Zhang W; Menestrier M; Klingel-Schmitt I; Michel O; Caillat-Zucman S; Aissaoui A; Landemarre L; Berrih-Aknin S; Cohen-Kaminsky S
J Clin Invest; 2003 Jul; 112(2):265-74. PubMed ID: 12865414
[TBL] [Abstract][Full Text] [Related]
2. Immunoregulation by Vbeta specific antibodies in myasthenia gravis: mining physiological T cell homeostasis for TCR specific therapy.
Jambou F; Cohen-Kaminsky S
Cell Mol Biol (Noisy-le-grand); 2003 Mar; 49(2):181-92. PubMed ID: 12887101
[TBL] [Abstract][Full Text] [Related]
3. Prospects for a T-cell receptor vaccination against myasthenia gravis.
Cohen-Kaminsky S; Jambou F
Expert Rev Vaccines; 2005 Aug; 4(4):473-92. PubMed ID: 16117705
[TBL] [Abstract][Full Text] [Related]
4. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of collagen-induced arthritis by DNA vaccines encoding TCR Vbeta5.2 and TCR Vbeta8.2.
Ge PL; Ma LP; Wang W; Li Y; Zhao WM
Chin Med J (Engl); 2009 May; 122(9):1039-48. PubMed ID: 19493438
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to glutamate receptor subtype 3 (GluR3) are found in some patients suffering from epilepsy as the main disease, but not in patients whose epilepsy accompanies antiphospholipid syndrome or Sneddon's syndrome.
Ganor Y; Goldberg-Stern H; Blank M; Shoenfeld Y; Dobrynina LA; Kalashnikova L; Levite M
Autoimmunity; 2005 Sep; 38(6):417-24. PubMed ID: 16278146
[TBL] [Abstract][Full Text] [Related]
7. Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls.
Link H; Olsson O; Sun J; Wang WZ; Andersson G; Ekre HP; Brenner T; Abramsky O; Olsson T
J Clin Invest; 1991 Jun; 87(6):2191-6. PubMed ID: 1904073
[TBL] [Abstract][Full Text] [Related]
8. TCR-Vbeta usage in the thymus and blood of myasthenia gravis patients.
Navaneetham D; Penn AS; Howard JF; Conti-Fine BM
J Autoimmun; 1998 Dec; 11(6):621-33. PubMed ID: 9878084
[TBL] [Abstract][Full Text] [Related]
9. The role of B-cells in experimental myasthenia gravis in mice.
Wang HB; Li H; He B; Bakheit M; Levi M; Wahren B; Berglöf A; Sandstedt K; Link H; Shi FD
Biomed Pharmacother; 1999 Jun; 53(5-6):227-33. PubMed ID: 10424244
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of overexpression TCR Vbeta5.2-HSP70 and TCR Vbeta8.2-HSP70 against collagen-induced arthritis in rats.
Xiao J; Li S; Wang W; Li Y; Zhao W
Cell Mol Immunol; 2007 Dec; 4(6):439-45. PubMed ID: 18163955
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis.
Klein R; Marx A; Ströbel P; Schalke B; Nix W; Willcox N
Hum Immunol; 2013 Sep; 74(9):1184-93. PubMed ID: 23792059
[TBL] [Abstract][Full Text] [Related]
12. Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice.
Yang H; Goluszko E; David C; Okita DK; Conti-Fine B; Chan TS; Poussin MA; Christadoss P
J Clin Invest; 2002 Apr; 109(8):1111-20. PubMed ID: 11956249
[TBL] [Abstract][Full Text] [Related]
13. Monozygotic twins discordant for epilepsy differ in the levels of potentially pathogenic autoantibodies and cytokines.
Ganor Y; Freilinger M; Dulac O; Levite M
Autoimmunity; 2005 Mar; 38(2):139-50. PubMed ID: 16040334
[TBL] [Abstract][Full Text] [Related]
14. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
[TBL] [Abstract][Full Text] [Related]
15. Anti-alkaline phosphatase antibody positive myasthenia gravis.
Konishi T; Ohta K; Shigemoto K; Ohta M
J Neurol Sci; 2007 Dec; 263(1-2):89-93. PubMed ID: 17628604
[TBL] [Abstract][Full Text] [Related]
16. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
Xiao BG; Duan RS; Zhu WH; Lu CZ
Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
[TBL] [Abstract][Full Text] [Related]
17. IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor.
Blaes F; Beeson D; Plested P; Lang B; Vincent A
Ann Neurol; 2000 Apr; 47(4):504-10. PubMed ID: 10762162
[TBL] [Abstract][Full Text] [Related]
18. Cell types required for anti-acetylcholine receptor antibody synthesis by cultured thymocytes and blood lymphocytes in myasthenia gravis.
Willcox HN; Newsom-Davis J; Calder LR
Clin Exp Immunol; 1984 Oct; 58(1):97-106. PubMed ID: 6236921
[TBL] [Abstract][Full Text] [Related]
19. T-bet deficiency decreases susceptibility to experimental myasthenia gravis.
Liu R; Hao J; Dayao CS; Shi FD; Campagnolo DI
Exp Neurol; 2009 Dec; 220(2):366-73. PubMed ID: 19818352
[TBL] [Abstract][Full Text] [Related]
20. [Antibodies in myasthenia gravis].
Eymard B
Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
